Novel coronavirus disease (COVID-19) in children

Turk J Med Sci. 2020 Apr 21;50(SI-1):592-603. doi: 10.3906/sag-2004-174.

Abstract

Coronavirus disease (COVID-19) was firstly reported at the end of 2019. The disease rapidly spread all around the world in a few months and was declared a worldwide pandemic by WHO in March 2020. By April 9, there were 1,436,198 confirmed COVID-19 cases in the world, nearly with 6% mortality rate. This novel infectious disease causes respiratory tract illness that may generally occur as mild upper respiratory tract disease or pneumonia. In older patients and/or patients with underlying conditions, it may result in acute respiratory distress syndrome, multi organ failure and even death. According to the current literature, children account approximately for 1%–5% of diagnosed COVID-19 cases. Generally, COVID-19 seems to be a less severe disease for children than adults. Approximately 90% of pediatric patients are diagnosed as asymptomatic, mild, or moderate disease. However, up to 6.7% of cases may be severe. Severe illness is generally seen in patients smaller than 1 year of age and patients who have underlying disesases. The epidemiological and clinical patterns of COVID-19 and treatment approaches in pediatric patients still remain unclear although many pediatric reports are published. This review aims to summarize the current epidemics, clinical presentations, diagnosis, and treatment of COVID-19 in pediatric patients.

Keywords: COVID-19; Novel corona virus; pediatrics.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Antiviral Agents / therapeutic use
  • Betacoronavirus
  • COVID-19
  • COVID-19 Drug Treatment
  • COVID-19 Testing
  • Child
  • Child, Preschool
  • Clinical Laboratory Techniques
  • Coronavirus Infections / diagnosis*
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / physiopathology*
  • Coronavirus Infections / therapy*
  • Humans
  • Infant
  • Infant, Newborn
  • Pandemics
  • Pediatrics*
  • Pneumonia, Viral / diagnosis*
  • Pneumonia, Viral / physiopathology*
  • Pneumonia, Viral / therapy*
  • Respiratory Therapy
  • Risk Factors
  • SARS-CoV-2

Substances

  • Antiviral Agents